Close
Digital Health & Ai Innovation summit 2026
Medical Taiwan 2026

Emirates Health Services announces ‘Care AI’ and ‘Digital Twin’ projects

Emirates Health Services (EHS) has launched the ‘Care AI’ and ‘Digital Twin’ projects which are the first of its kind in the region while taking part in the Arab Health Exhibition and Congress (Arab Health 2023), which kicked off at the Dubai World Trade Centre on 30 January and will run until 2 February. EHS is participating in this year’s event under the theme ‘Shaping the future of healthcare’.

Her Excellency Mubaraka Ibrahim, Acting Chief Information Officer at Emirates Health Services, said: “The Care AI project is one of the latest and most advanced technology projects announced by Emirates Health Services. It consists of a basic system for a smart healthcare facility, supported by artificial intelligence for self-monitoring, tracking patient behaviour and movement, and assisting doctors in diagnosing patients using computer vision, in addition to automatically updating and analysing patient data. Care AI also allows for using AI technology based on the patients’ condition to continuously improve care based on collected information.”

“The project independently evaluates and tracks the extent of compliance with approved health and safety protocols across EHS’ affiliated facilities, in order to collect immediate information about the extent to which safety protocols are implemented, as well as to analyse and evaluate the patient’s condition, and monitor procedures followed while providing healthcare to patients,” H.E. added.

Digital Twin Project

The Digital Twin project, which Emirates Health Services is implementing in partnership with Schneider Electric and Microsoft, forms part of the comprehensive digital transformation EHS is leading in the health services it provides. Emirates Health Services established ‘Digital Twin’ for Al Qassimi Hospital, which aims to enhance EHS’ efforts towards sustainability and reduce the carbon footprint of its facilities, cutting energy consumption by up to 30% and reducing breakdowns and maintenance work by up to 20%.

H.E. Mubaraka Ibrahim stated that the project aims to highlight the role that Digital Twin in driving sustainability across EHS’ health facilities, by focusing on monitoring and reducing carbon emissions, which, in turn, affects climate change, in line with the sustainable development goals adopted by the United Nations and the UAE.

The Acting Chief Information Officer at EHS explained the notable role that the project plays in improving tracking for energy used inside buildings, while comparing different patterns, such as the nature of the facility, to detect areas of potential improvement, determine priorities for modernisation and spending, and identify opportunities for using renewable and clean energy. The model can control and predict the optimal use of renewables, such as solar power, and adding it to energy derived from the electricity grid, so that reliance on renewable energy is maximised without affecting the stability of the system and business continuity.

Where Can I Buy Cribs Online?

Preparing for your newborn to arrive is a very exciting yet stressful time. There’s so much to think about and if you are a new-mum-to-be, the pressures of getting it right can be too much to handle. Your crib will become one of the most important parts of your child’s bedroom, offering them comfort and assisting their development. With that in mind, we’re taking a closer look at what to look out for when buying a crib online from considering the durability of your chosen crib, to the mattress that’s inside.

Durability

Your baby’s first crib is so important, aiding their growth and development and ultimately becoming their ‘safe space’. With that in mind, it’s likely that your chosen crib will experience pressure and even damage during the time it’s used, highlighting the importance of making a durable selection. Pinewood is one of the safest and most durable options, giving you the option to paint it should you so wish. If you are purchasing a crib second hand, make sure that it’s no older than 10 years old. Cribs 10 years old or older may be broken or have wider gaps between side slats, creating a higher health risk.

Firm Mattress

To maximise your baby’s development, your crib should feature a firm, tight-fitting mattress. This is especially true as they start to become more active, as the firm surface will help to provide greater resistance as they begin to turn and stand. Firm mattresses also put less strains on your baby’s bones and spine, allowing optimum oxygen intake whilst sleeping. Be sure to research the best crib mattresses for a comfortable and safe sleep.

Top tip: Though it can be tempting to deck out your baby’s crib with stuffed toys, pillows and comforters, avoid placing soft products with them as they sleep. Doing so may increase the chance of suffocation.

Functionality

One of the most important things to consider before buying a crib is its function. Wooden cribs generally offer greater functionality compared to metal cribs, growing with your baby as they develop. That way, you won’t have to buy a new crib or bed quite as soon and it is budget friendly.

Cost

When expecting your newborn, it can be tempting to spend over budget on luxurious items that you don’t necessarily need but look good. When buying a crib online, consider how much you want to spend. For example, if you are looking for a multi-functional crib, you may decide to increase your budget as you know that it will be suitable throughout the early years of your child’s life. At the same time, you also want to consider the quality of the crib you want to buy. Consider its hardware, cutouts, slat placement and corner posts.

Reviews

Buying a new crib online can be difficult and overwhelming, particularly if this is your first time. One of the best ways to make sure you get it right is by reading what other parents have written about said cribs. Online reviews tell you more about the product in question, showcasing other new mums and dads experiences, helping you to make an informed decision before purchasing. It can also reassure you about the product in question, helping to make sure your baby remains happy and healthy in their first bed.

For Construction Leaders, Workplace Health, Safety Pivotal

Some of the biggest construction companies across Australia have announced a funding partnership with a medical research charity called The Common Good to develop a tradie health institute. The companies have been invited to be the founding members of this initiative, which happens to be a world first because of their thrust to provide safety and health programmes at the work sites.

CEO of the Common Good, Michael Hornby, stated that they wanted to function only with those companies that were clear when it came to valuing their tradespeople. He added that the companies that take health as well as safety seriously are the ones that acknowledge the issues and also have the capabilities to aid other businesses as well as contractors.

The coming on-board of industry leaders will provide the base investment for Tradie Health Institute with an aim to thwart silicosis which happens to be a lung disease that may very well be impacting more than 600,000 retires as well as currently working tradies.

Mark Baker from BESIX Watpac remarked that they clearly accepted the offer of being the first founding partner based on the inclination they have for health and other safety measures.

They had set up the BESIX Watpac community fund in 2022, which included supporting community health. They now have an opportunity to not only look into the wellbeing of their staff and contractors but to make a difference that is meaningful for tradespeople based across Australia who have already been diagnosed with lung disease that is trade-related. He added that there are many businesses out there that have not undertaken the right measures or were not aware of the risks, and he now calls on other CEOs to stand with this initiative to support the Tradie Health Institute and its drive against silicosis and other lung conditions that are occupational.

The tradie health institute happens to be a collaboration with one of Australia’s largest lung hospitals and is the only institute that powers medical discoveries to aid the tradespeople and companies in construction, mining, and agriculture.

Celularity Receives Preliminary Assessment of Product Classification and Jurisdiction For Its Investigational Celularity Tendon Wrap (CTW)

Celularity Inc. (“Celularity” or the “Company”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, announced that, in response to its October 2022 Pre-Request for Designation (Pre-RFD) for its investigational Celularity Tendon Wrap (CTW), the U.S. Food and Drug Administration (FDA) has reviewed information provided by the Company and other relevant available information, and agreed with the Company’s recommendation that its investigational CTW product be regulated as a device by the FDA Center for Devices and Radiologic Health (CDRH). The FDA feedback is preliminary and non-binding. Celularity intends to submit a 510(k) application for regulatory clearance to CDRH by the end of 2023.

Celularity’s 510(k) submission to CDRH for CTW is intended to be for the management and protection of tendon injuries in which there has been no substantial loss of tendon tissue as a structural barrier for injured tendon tissue, and does not depend on chemical action to mediate this effect, to be classified as a surgical mesh.

“We are delighted to receive this feedback from the FDA on preliminary CTW product classification and CDRH jurisdiction,” said Robert J. Hariri, M.D., Ph.D., Celularity’s CEO, Chairman and Founder. “Our unique business model continues to generate innovative therapeutic products from the biomaterials and stem, progenitor and immune cells derived from the placenta. We have had a history of developing and commercializing products for degenerative diseases and see great potential to use this part of our business as a revenue engine to help support continue research and development as well as enhance the value proposition for our investors. We will work with the FDA to provide the appropriate pre-clinical data to support a 510(k) pre-market notification submission later this year, and expect to launch our product in 2024.”

As part of its CTW Pre-RFD submission, Celularity also provided supporting data demonstrating that its proprietary processing steps are designed to remove from CTW all cells, cellular debris, residual nucleic acids, cytokines and chemokines, residual hormones, growth factors and other regulators of wound healing, scarring and fibrosis, and well as anti- and pro-inflammatory factors.

The global tendon repair market was valued at $2.1 billion in 2021 and is expected to exhibit a compound annual growth rate (CAGR) of 7.5 percent through 2030, according to a 2022 report by Grand View Research. In terms of regional breakdown, in 2021 North America accounted for the highest revenue share, $821.1 million or 45.2 percent.

About 510(k) Submission

A 510(k) submission refers to Section 510(k) of the Food, Drug and Cosmetic Act, which requires device manufacturers to notify FDA of their intent to market a medical device at least 90 days in advance. This is known as Pre-market Notification, also called PMN or 510(k). This allows FDA to determine whether the device is equivalent to a device already placed into one of the three classification categories. Thus, “new” devices (not in commercial distribution prior to May 28, 1976) that have not been classified can be properly identified.

Celularity’s Advanced Biomaterial Products

Celularity markets a suite of commercial placenta-derived biomaterial products. Most recently, the Company announced an exclusive territory agreement with CH Trading Group, an international import, export, and trading company, to distribute Celularity’s branded regenerative biomaterial products — which are Halal-Certified under globally recognized Circle H International Inc. standards — in more than 100 countries.

Celularity’s advanced biomaterial products include:

  • Biovance®, a decellularized, dehydrated human amniotic membrane derived from the placenta of a healthy, full-term pregnancy. Biovance® is an intact, extracellular matrix structure that is indicated for use in the United States as a natural scaffold to support the body’s wound healing process.
  • Biovance® 3L and Biovance® 3L Ocular, tri-layer human amniotic membrane products focused on the surgical and ocular markets and available in both sheet and disk form.
  • Interfyl®, a human connective tissue matrix derived from the placenta of a healthy, full-term pregnancy. It is indicated for use in the United States to replace or supplement damaged or inadequate integumental tissue resulting from wounds, trauma, or surgery.
  • CentaFlex®, a decellularized human placental matrix derived from the umbilical cord that is indicated for use in the United States as a surgical covering, wrap or barrier to protect and support the repair of damaged tissue.

6 Legal Facts To Know When Fighting Cancer

Facing a cancer diagnosis is an incredibly difficult and stressful experience. It can be overwhelming to navigate the legal aspects of your situation in addition to managing medical care, financial concerns, and emotional stress. However, understanding your rights as a patient can help you feel more in control of the process and make sure you receive the best possible treatment for your individual needs. Here are six important legal facts that everyone with cancer should know before starting their journey.

1. You Have the Right to Access Your Medical Records and Request a Second Opinion

As soon as you receive a diagnosis, it’s important to review your medical records and understand the details of your situation. You have the right to request copies of your records and take them to a specialist for a second opinion if desired. Especially since you are dealing with cancer, it’s important to get as much information as possible in order to make the best decisions for your care. A second opinion can also provide reassurance that the initial diagnosis is accurate. Most importantly, you should never be hesitant to ask questions and have conversations with medical professionals about your condition.

2. You Can Obtain Information About Available Clinical Trials for Cancer Treatments

Clinical trials are an important way to gain access to promising treatments that may not yet be available on the market. Through clinicians, researchers and scientists can test the effectiveness of a new medicine or therapy for cancer treatment. There are strict criteria for eligibility, so it’s important to make sure you meet the requirements before signing up for a trial. You can start by visiting the ClinicalTrials.gov website to learn more about available studies in your area. Furthermore, you have the right to know all of the details of any trial you may choose to participate in.

3. You May be Entitled to Free or Reduced Cost Care if You Are Uninsured or Underinsured

The cost of cancer treatment can be incredibly expensive, so it’s important to research your options for financial assistance. The federal government and many states offer programs that provide free or reduced-cost care if you do not have insurance or are underinsured. Additionally, non-profits may be able to provide additional resources for those in need. It’s important to do your research and take advantage of any available options if you’re facing financial hardship. Moreover, speak to your doctor about other treatment options if cost is a concern.

4. You Can Hold Doctors Liable for Resulting Injuries as a Result of Negligence

If you believe that your doctor or medical team has been negligent in their care, you may have the power to hold them accountable. This means that if a medical professional’s actions caused an injury or worsened your condition, they can be held financially responsible for the harm they caused. It’s important to speak with a lawyer who specializes in malpractice in order to determine if you have a case. Furthermore, you can also file a complaint with the state medical board if you believe that a doctor or hospital has acted inappropriately.

5. You May Qualify for Financial Assistance or Disability Benefits

Patients with cancer may qualify for Social Security disability benefits if they are unable to work due to the severity of their condition. Additionally, there are numerous organizations that offer financial assistance programs to help cover the cost of medical bills and treatments. It’s important to take advantage of any available resources in order to reduce the financial burden that comes with a cancer diagnosis. Moreover, many non-profits have volunteer opportunities where you can earn extra money that can be used for medical expenses.

6. You Have the Right to Refuse Any Recommended Treatments without Fear of Retribution

At the end of the day, you have the right to make decisions about your own body and care. If you are uncomfortable with any treatments that are recommended by your doctor, you can refuse them without fear of retribution. Furthermore, it’s important to remember that you always have the right to a second opinion or to seek additional information before making any final decisions. Ultimately, it’s important to trust your gut and make sure that the treatment you receive is in line with your wishes.

No matter what path you choose, the most important thing is that you have an informed understanding of all of your rights as a patient. As long as you are well-informed and aware of the legal aspects of fighting cancer, you can make decisions that are best for your own well-being. By taking advantage of available resources and knowing your rights, you can ensure that you have a positive outcome in your cancer fight.

What Should Parents Do After a Birth Injury: 4 Steps to Follow

Giving birth is one of the most wonderful and miraculous experiences a woman can have. But unfortunately, sometimes things don’t go as planned and an injury may occur during labor or delivery. These injuries can range from mild to severe and can cause long-term health issues for both mother and baby.

When a birth injury occurs it is important for parents to understand their legal rights and options, so they can seek justice if necessary. This article will discuss how parents should deal with a birth injury including what type of compensation they may be entitled to receive as well as where they can turn for help if needed.

Understanding Birth Injuries

Birth injuries are usually caused by medical negligence or mistakes made by healthcare professionals during labor or delivery. They often result in physical trauma to the baby, such as broken bones, bruising, fractured skulls, brain damage, paralysis, and even death in some cases. In addition to physical trauma, there are also many types of non-physical birth injuries that can be caused by medical errors such as hypoxia (lack of oxygen) or cerebral palsy due to lack of proper monitoring during childbirth. If a birth injury is caused by medical negligence, the family may be entitled to compensation for any medical bills, pain, suffering, or even wrongful death.

Choosing The Right Lawyer

When dealing with a birth injury, it is important for parents to find a qualified attorney who can help them understand their rights and protect them from any possible legal issues. A good lawyer should be knowledgeable in medical malpractice law and be willing to work closely with the family during each step of the process. The right lawyer can also provide guidance on how to obtain compensation from the healthcare provider or insurance company. When searching for a birth injury lawyer in Cincinnati or any other place, it’s important to research each option carefully to ensure that the chosen attorney is experienced and has a successful track record in fighting such cases. They should also be sure to get an accurate estimate of the total legal fees upfront.

Seeking Compensation For A Birth Injury

If a birth injury was caused by medical negligence, the family may be able to receive compensation. Depending on the state where the injury occurred, the compensation may also cover lost wages and other expenses related to the injury. Additionally, some states have a statute of limitations for filing a medical malpractice lawsuit, so it is important to speak with an attorney as soon as possible following the incident in order to determine eligibility. When dealing with a birth injury, it is essential to have all information and documentation related to the injury in order to ensure that the family receives the maximum amount of compensation they deserve.

Getting the Help You Need

Dealing with a birth injury can be an emotionally and financially draining experience for any family. Fortunately, there are a number of resources available to help families seek justice and understand their legal rights in the event of medical negligence. Parents should contact their local bar association or state attorney general’s office to learn more about filing a medical malpractice lawsuit or getting the help they need when it comes to dealing with a birth injury. Additionally, there are many nonprofit organizations that offer free legal advice and assistance for families dealing with birth injuries. With the right information, support, and resources, parents can ensure that their family is taken care of in the event of a birth injury. It’s important to remember that justice is possible and that no family should ever have to experience the pain and suffering caused by medical negligence. There are many support groups available to help families through difficult times and answer any questions they may have.

With the right legal representation, parents can hold those responsible for their child’s injury accountable. In addition to seeking justice, financial compensation can also be critical for helping with medical bills or other costs related to a birth injury. No family should ever have to face the emotional and financial burden of a birth injury alone. With the right support, understanding, and resources, parents can get the help they need to pursue justice and protect their families. If you or a loved one has been affected by a birth injury, contact an experienced attorney to learn more about your rights. They can help you understand the legal process and ensure that your family is taken care of.

Getting back to business – Let’s meet in Bangkok!

MEDICAL FAIR THAILAND 2023 | 13-15 September

Preparations are in full swing as MEDICAL FAIR THAILAND makes its way to Bangkok once again in 2023. After a three-year break, the 10th edition of the exhibition will run its physical edition from 13 to 15 September at BITEC, followed by a 7-day digital extension where exhibitors and visitors can engage further online through its AI-powered business-matching system until 22 September. This is the first time MEDICAL FAIR THAILAND will be held in a ‘phygital format’.

Highlights this year include signature showcases such as the Community Care Pavilion and Start-Up Park, and also the introduction of the Medical Manufacturing pavilion. As the region’s leading specialist trade fair for the medical and healthcare sectors for the past two decades, MEDICAL FAIR THAILAND serves the full value chain and end-to-end needs of the medical and healthcare sectors. From diagnostics, wearable technology, connected healthcare solutions, rehabilitation and therapy equipment, 3D printing technology, and now – medical technology (MedTech) components, processes and solutions – the exhibition offers the ideal destination for medical and healthcare buyers and professionals looking to meet their sourcing objectives, gain industry insights and to share best practices.

“We have been waiting for three years so we are excited and are gearing up for a big comeback for MEDICAL FAIR THAILAND 2023. With the positive feedback, industry commitment, and almost 80% bookings received for 2023, we should be on track to reach close to pre-pandemic levels by next year. On the back of a highly successful and well-received phygital edition of MEDICAL FAIR ASIA that was held in Singapore earlier this year, and as we navigate further in a post-pandemic landscape, we are confident by this year the industry will be more than ready to move into high gear and Thailand will be an ideal location.”

 – Gernot Ringling, Managing Director, Messe Düsseldorf Asia.

MEDICAL FAIR THAILAND 2023 comes against a strengthening backdrop where Thailand continues to firm its position as a medical hub of the region with its supportive government policies and incentives, making it a model investment destination for a wide range of medical and healthcare service sectors. In line with Thailand’s 4.0 policy, the Thai government considers the healthcare industry to be a priority sector for investment, thus the staging of MEDICAL FAIR THAILAND 2023 is well-positioned.

To find out more, go to www.medicalfair-thailand.com

New! Medical Manufacturing Pavilion

A special themed pavilion focused on medical manufacturing processes and components – from new materials, intermediate products, packaging and services, to microprocessors and nanotechnology. With Thailand’s growing reputation as a production and distribution base of medical devices both within and outside Thailand, it has become a natural market for medical devices. According to data from the Office of Industrial Economics, Ministry of Industry (Medical Devices Intelligence Unit), there is much potential for investment opportunities in sophisticated medical devices particularly due to Thailand’s reliance on imports for this segment.    






Community Care Pavilion  special focus on mental health

With a special spotlight on mental health with a showcase featuring digital mental health technologies, from smart medicine to therapeutic medical equipment. Its mainstay of addressing the needs of ageing societies on the back of rising chronic diseases and an ageing population, the pavilion will also feature a full suite of geriatric medicine, rehabilitative equipment, assistive technology, and mobility products. Thailand’s proportion of citizens aged over 60 years, is forecast to be one of the highest in ASEAN by 2045, and will also exceed countries such as Europe and the United States. Thailand’s fast-increasing ageing population and the estimated more than three million Thais suffering from poor mental health, is expected to further drive the demand for related healthcare services.  		Start-up Park

A strategic platform for companies with ready-to-market healthcare solutions to meet relevant buyers and partners, industry influencers, experts, and potential investors. From innovative healthcare industry solutions, health apps and new tools for gathering and AI-supported analysis of health data, to robotic assistance systems and new approaches in diagnostics – the Start-Up Park is a must-attend for SMEs looking to scale-up their business. The Start-Up Park plays a significant role as an enabler of the entrepreneurial ecosystem that encourages life sciences and medical and health innovation in Thailand. With the country’s vibrant start-up landscape propelled further by the government’s numerous grants and new regulations as part of Thailand’s ambitious plans to be a start-up-based country, the start-up scene has grown systematically over the years and is considered one of Asia’s hidden gems.  At the last edition of MEDICAL FAIR THAILAND held in 2019, a total of 11 start-up companies participated from Singapore, Japan, South Korea, Hong Kong, Taiwan and Thailand.  

Risk Adjustment Policies Issued By CMS To Check Overpayments

To avoid making additional payments to Medicare Advantage Organizations, the Centers for Medicare and Medicaid Services approved risk adjustment policies in a regulation.

According to studies and audits conducted separately by CMS and the Health and Human Services Office of Inspector General, the medical records of Medicare Advantage enrolees do not always support the diagnoses reported by MAOs, resulting in billions of dollars in overpayments to plans and higher costs for the Medicare program as well as taxpayers.

The CMS declared that no risk adjustment overpayments have been obtained from MAOs since the payment year 2007.

On January 30, 2023, CMS released the Risk Adjustment Data Validation final rule, which holds insurers accountable.

Instead of starting to extrapolate for 2011 audits, as CMS suggested, they’ve decided not to extend RADV audit findings from 2011–2017 and will begin extending from the 2018 RADV audit.

So, CMS will only collect the overpayments uncovered in their RADV audits and OIG investigations from 2011 to 2017. They’re finalising their proposed policy of not including the fee-for-service adjuster in RADV audits.

The requirement of actuarial equivalence in Medicare Advantage (MA) payments is relevant to how CMS risk-adjusts the payments they make to MAOs, not to the duty to repay overpayments for unsupported diagnosis codes, including those determined during a RADV audit, according to the 2021 D.C. Circuit Court ruling in UnitedHealthcare Insurance Co. v. Becerra.

According to the agency, the revised regulations would allow CMS to continue focusing its audits on MAOs that have been recognised as having the highest risk of making wrong payments.

The CMS has issued the RADV Final Rule as a consequence of its consideration of numerous public comments and robust stakeholder interaction following the publication of the 2018 Notice of Proposed Rulemaking.

Insurance companies informed the CMS in September 2022 that the planned RADV policies were unfair because they focused on earlier audits from ten years prior. The American Health Insurance Plans complained to CMS that the proposed changes to the Risk Adjustment Data Validation audit weakened trust in CMS’s commitment to reasonably working with the private sector.

On January 30, America’s Health Insurance Plans declared that their final rule is still unlawful and fatally flawed.

The rule is regarded as illegal and gravely faulty, according to Matt Eyles, President and CEO, and should have been retracted rather than finalized. It will harm the elderly, diminish health equity, and discriminate against people who require special care. Furthermore, it will raise fees for seniors and taxpayers, lower benefits for those who choose MA, and result in fewer plan options in the future. He urged CMS to work with them to protect the American people’s health and financial stability.

The CMS primarily audits and oversees MA payments through the Medicare Advantage Risk Adjustment Data Validation program.

CMS’ compensation to MAOs is adjusted by the medical state of participants, as indicated by the medical diagnosis reported by MAOs.

CMS must collect overpayments across all of its services, and payments to MA plans made in error are not exempt, according to HHS Secretary Xavier Becerra. For many years, federal regulators and external specialists have determined that the Medicare Advantage programme is among the most significant administrative and operational difficulties facing the Department of Health and Human Services, and they are now taking the necessary actions to audit and reclaim resources.

Ventana Research Awards InterSystems IRIS an “Exemplary” Rating and a Top Ranking in its 2023 Value Index for Data Platforms Report

InterSystems, a creative data technology provider dedicated to helping customers solve the most critical scalability, interoperability, and speed problems, today announced that Ventana Research’s Value Index for Data Platforms awarded InterSystems IRIS® data platform with its highest rating of “Exemplary,” and ranked it third overall from among thirteen total vendors.

The Ventana Research 2023 Value Index for Data Platforms provides an independent, holistic view of thirteen vendors’ ability to serve a combination of both operational and analytic workloads with either a single data platform product or multiple data platform products. In the report, InterSystems IRIS ranks third overall, and second in the Product Experience, Usability, and Adaptability categories.

Matt Aslett, VP & Research Director at Ventana Research said, “As a cloud-first data platform, InterSystems IRIS can reduce the need to implement and integrate multiple technologies, resulting in less code, fewer system resources, and less maintenance. I recommend that organisations that are migrating to the cloud and are looking for a platform to provide a consistent, accurate and real-time view of their enterprise data should evaluate InterSystems.”

InterSystems success reflects its ability to provide native analytic and operational capabilities in a single product. The next generation InterSystems IRIS data platform provides built-in high performance database management, interoperability, and analytics capabilities, and eliminates the need to copy data from an operational database to a separate analytic database.

The second-place ranking for the Adaptability category demonstrates InterSystems commitment to meeting customer requirements and high rates of customer satisfaction. Using InterSystems IRIS, developers are able to use their programming language of choice, while Embedded Python support enables Python developers to gain direct server-side access to all of the functionality in the platform, providing a familiar programming environment for the more than eight million Python developers worldwide.

InterSystems IRIS ability to meet the varying business needs of executives, management, workers and analysts, along with IT and others involved in data platforms contributed to achieving a ranking of second in the Usability category. It was also ranked second in Product Experience.

Joe Lichtenberg, Global Head of Product and Industry Marketing, InterSystems, said: “We are delighted that our InterSystems IRIS data platform has been recognised as third overall among the top thirteen data platform vendors by Ventana Research, as well as recognising InterSystems as an “Exemplary” vendor. In today’s landscape, data platforms are essential to support concurrent operational and analytical workloads to ensure organisations obtain the real-time data and insights they need to manage disruptions, identify new opportunities, and move their businesses forward. Coming out ahead of well-respected vendors such as Microsoft, Amazon, SAP, and Google in Ventana Research’s overall ranking is testimony to InterSystems deep commitment to our customers’ success, and our ability to deliver the functionality, performance, usability, and reliability our customers require.

To access the Ventana Value Index for Data Platforms report, visit: www.InterSystems.com/Ventana.

Hexarelin And GHRP-6: Cardiovascular Wellness Winner?

GHRP-6 Vs. Hexarelin- Which one is the winner in the cardiovascular wellness battle? If you are interested to know the answer, please keep reading. Without further ado, let’s begin!

In animal studies, growth hormone-releasing peptides, or GHRPs, are synthetic sequences of amino acids that trigger the release of growth hormones. Researchers have not yet figured out how they function. It has been hypothesized that they may affect both the pituitary and hypothalamus glands.

The antioxidant properties of GHRPs have been studied, and the results suggest that they have cardioprotective and cytoprotective effects through lowering inflammation. This article compares and contrasts hexapeptides, Hexarelin, and GHRP-6, focusing on their effects on growth hormone release and their work method.

What Is Hexarelin?

Hexarelin is a newly synthesized GHRP that is a near relative of GHRP-6. It is a synthetic analog of ghrelin, a peptide with 28 amino acids, and has been designed to stimulate growth hormone release. It is very similar to GHRP-6 and is thus a synthetic analog of ghrelin.

Hexarelin and GHRP-6 are structurally identical except for GHRP-6’s addition of two methyl groups. Because of its very selective mechanism of action, this peptide may be taken orally or sublingually without losing its efficacy. Because of its effect on cardiac cell survival after ischemia and nutritional restriction, it has been the subject of substantial research.

Comparatively, its biological action is more significant, and its stability is higher than that of ghrelin. It’s a peptide made up of only six amino acids, and its sequence is (His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2). With a molecular weight of 887 g/mol and an empirical formula of C47H58N12O6, this substance is rather heavy for its size.

Through phospholipid-dependent protein kinase (PKC) signaling, Hexarelin causes hormone release in animal test subjects by binding to particular receptors in the pituitary and hypothalamus. It binds to and activates the cardiac receptors CD36 in a manner analogous to that of ghrelin, which stimulates the release of growth hormone from the pituitary gland.

What Is GHRP-6?

Met-enkephalin is the precursor of Growth hormone-releasing peptide-6, a first-generation synthetic hexapeptide. Consists of a series of 6 artificial D amino acids in the order (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2). This hexapeptide was discovered almost a decade ago, making it the pioneering hexapeptide to be explored in animal model research.

GHRP-6 finds its target receptors in the hypothalamus and pituitary. Research has shown that GHRP-6 receptors are widely distributed in many peripheral organs, including the heart, adrenal glands, ovaries, testes, lungs, and skeletal muscles.

The empirical formula for this peptide is C46H56N12O6, and its molecular weight is 873 g/mol.

Mechanism Of Action

Evidence from animal studies suggests that GHRP-6 acts on a receptor distinct from that of endogenous Growth Hormone-Releasing Hormone that activates ghrelin, hence increasing GH synthesis in the pituitary or brain (GHRH).

The pituitary gland, the central nervous system, the liver, and the stomach play essential roles in GHRP-6 studies.

Cardioprotective Hexarelin

Experimental evidence in mouse models demonstrates that Hexarelin shields cardiac cells from damage during cardiac arrest. The protein inhibits cardiac cell death by interacting with CD36 receptors. Increased cardiac cell survival and decreased malondialdehyde levels are two ways the peptide aids in bettering heart function (cardiac cell death marker).

Hexarelin has enhanced cardiac function in diabetic rat models by influencing how the heart’s muscle cells handle calcium and potassium. Interestingly, the research also shows that GHRP-6 is more effective than ghrelin.

By causing a shift from a sympathetic (increased blood pressure, heart rate, etc.) to a parasympathetic (normalized) nervous system response, GHRP-6 facilitates cardiac remodeling. Short-term health and results are improved, and the requirement for long-term cardiac medicine and scar tissue repair is reduced, thanks to this control.

GHRP-6 And Muscle safety

This peptide effectively protects muscle cells in general, not only the heart. Cachectic rat muscle GHRP-6 regulates calcium flow and mitochondrial dysfunction (extreme weight loss due to illness or chemotherapy). Protecting mitochondria helps keep muscle cells alive as well. Following chemotherapy, calcium ion levels are often altered, and GHRP-6 may aid in restoring standard control of these levels.

Reductions in Body Fat Measures And GHRP-6

Blood lipid levels that are too high are a physiologic disorder known as dyslipidemia. Improved glucose homeostasis and insulin sensitivity are two of the many benefits rats get with GHRP-6. Consequently, researchers may utilize it in place of current lipid medicines to treat severe dyslipidemia.

GHRP-6 Vs. Hexarelin

The effects of these peptides are almost identical in animal studies. Weight reduction, increased lean muscle mass, cardiovascular protection, speedier healing from accidents, etc., are all effects of both.

While GHRP-6 is effective in stimulating growth hormone (GH), adrenocorticotropic hormone (ACTH), cortisol, and prolactin, Hexarelin is preferred due to its ability to do so even while the subject is asleep. Hexarelin does not affect plasma glucose, luteinizing hormone, follicle-stimulating hormone, thyroid-stimulating hormone, or insulin-like growth factor-1. In contrast to GHRP-6, it does not increase ghrelin and has a longer half-life.

If you are a licensed professional interested in buying these peptides for your study, you can visit Core Peptides’ website.

1...242243244...1,130Page 243 of 1,130

About us

Hospital & healthcare Management is a leading B2B arena designed for the healthcare sector, it allow members to reach both ends of the healthcare facility procurement chain. . . Read More

Subscribe us

System

Resources

Archive Links

Subscribe

Copyright © 2008 - 2026 Hospital & Healthcare Management. All rights reserved. Publication of Leo Marcom Pvt Ltd.

Translate »